RESILIO THERAPEUTICS, LLC
Biotech · Private
DFMO (difluoromethylornithine) therapeutic for autosomal dominant polycystic kidney disease
- Grants
- $2.4M
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 2 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Novel, Orally-Available Prodrugs for Alzheimer's Disease | $983,466 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel, Orally-Available Prodrugs for Alzheimer's Disease | $875,154 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Therapy for Huntington's Disease | $240,750 | |
| Federal grant | Department of Health and Human Services · Phase I · DFMO Therapy for Polycystic Kidney Disease | $299,934 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3261 | Tessa Therapeutics | — | — |
| 3262 | Oblenio Bio | — | — |
| 3263 | Aplexis, Inc. | — | — |
| 3264 | RESILIO THERAPEUTICS, LLC | — | — |
| 3265 | GCFREE, INC. | — | — |
| 3266 | NIGHTSTAR BIOTECHNOLOGIES, INC | — | — |
| 3267 | ROCK IMMUNE LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compounds And Methods For The Treatment Of Neurodegenerative Diseasesgranted
- Compounds And Methods For The Treatment Of Polycystic Kidney Disease (pkd)application
- Compounds And Methods For The Treatment Of Neurodegenerative Diseasesgranted
- Compounds And Methods For The Treatment Of Neurodegenerative Diseasesapplication
- Compounds And Methods For The Treatment Of Polycystic Kidney Disease (pkd)application
- Compounds And Methods For The Treatment Of Neurodegenerative Diseasesapplication
- Compounds And Methods For The Treatment Of Neurodegenerative Diseasesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.